Janssen discontinues two Alzheimer's trials for BACE inhibitor

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said it is discontinuing two trials testing atabecestat (JNJ-54861911) to treat Alzheimer's disease after an evaluation showed the therapy led to elevated liver

Read the full 336 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE